Imexpharm Corporation
HHOSE:IMP35,600.00
VND
0.00
(0.00%)
ISIN
VN000000IMP0
Return %
Stock
S&P 500
1Y
-28.44
14.20
3Y
28.39
81.12
5Y
11.28
68.34
Capital Structure
VND
•
in mil. unless spec.Working Capital
VND
•
in mil. unless spec.Growth Rates
VND
•
in mil. unless spec.Quarterly Revenue
VND
•
in mil. unless spec.Quarterly Earnings Per Share
VND
•
in mil. unless spec.Quarterly Dividends Per Share
VND
•
in mil. unless spec.Company Description
- CEO
- Dao Thi Tran
- Full Time Employees
- 1,456
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cao Lanh Vietnam
- IPO Date
- Dec 4, 2006
- Website
- imexpharm.com
- Similar Companies
- Business
- Imexpharm Corporation is a Vietnam-based pharmaceutical manufacturing company founded in 1977 and headquartered in Cao Lanh City, Dong Thap Province, Vietnam. The company specializes in the research, development, formulation, contract manufacturing, and commercialization of generic and branded pharmaceutical products across ethical prescription (ETC) hospital tenders and over-the-counter (OTC) retail pharmacy channels. Its core product portfolio covers a diverse range of therapeutic categories, including: anti-infectives and antibiotics, comprising oral and injectable cephalosporins, penicillins, and broad-spectrum formulations marketed under brands such as Claminat, Bacsulfo, Imexime, Pharmox, and Biocemet; cardiovascular and metabolic therapies for hypertension, hyperlipidemia, and diabetes management; respiratory tract treatments, mucolytics, and antihistamines; analgesics, antipyretics, and anti-inflammatory medications, including the A.C Mexcold and Andol Fort product lines; gastrointestinal agents and digestive tract treatments, such as ALU-P Gel; central nervous system therapies; ophthalmological solutions; musculoskeletal treatments; and nutritional health products, including vitamins and mineral supplements. Imexpharm manufactures these preparations in multiple dosage forms, such as film-coated tablets, hard and soft gelatin capsules, dry syrups, oral suspensions, lyophilized powders for injection, and sterile liquid ampoules produced via Blow-Fill-Seal (BFS) technology. The company operates four modern manufacturing factory clusters across Dong Thap Province, Binh Duong Province, and Ho Chi Minh City, maintaining the largest network of European Union Good Manufacturing Practice (EU-GMP) certified production lines in Vietnam, serving domestic healthcare institutions and exporting to regional and international markets, including Singapore, Malaysia, the Philippines, Mongolia, and select European Union jurisdictions. In recent major corporate developments, Imexpharm transitioned ownership following South Korea-based SK Group's divestment of its controlling interest to Lian SGP Holding Pte. Ltd., a subsidiary of China-based Livzon Pharmaceutical Group Inc. The company is actively executing substantial industrial expansion, including the construction of the VND 1.5 trillion Cat Khanh Pharmaceutical Factory Complex (IMP5) in Dong Thap Province, designed to produce up to 1.4 billion units annually with a dedicated focus on high-potency non-antibiotic oral solid dosage forms and complex injectables. Additionally, Imexpharm continues to expand its portfolio of high-value first-generic medicines, secure new European marketing authorizations, and advance strategic technology transfer and distribution partnerships with multinational pharmaceutical enterprises, including Sandoz, Sanofi, and Genuone Sciences.